Golden Helix Inc.

Golden Helix Inc., a for-profit bioinformatics software company headquartered in Bozeman, Montana, licenses genomic data analysis software to federal health research agencies as a prime contractor on a full-and-open basis, with no subcontract footprint and no small business set-asides across its federal work. The company sells perpetual and renewable licenses to its SNP & Variation Suite (SVS), VSClinical, VarSeq, and VarSeq Pharmacogenomics (VSPGX) software platforms, which enable federal laboratory researchers to process, analyze, and interpret large-scale next-generation sequencing data for genomic and pharmacogenomic research and clinical applications.

Golden Helix's federal customer base concentrates heavily within the Department of Health and Human Services. The top five customer offices account for 68% of combined potential value across the seventy-nine awards in the source, led by the National Human Genome Research Institute (NHGRI) with twenty-three awards valued at $342 thousand in combined potential value, followed by the NIH Office of Logistics and Acquisition Operations (four awards, $181 thousand), the National Eye Institute (five awards, $114 thousand), NIH general (two awards, $96 thousand), and the CDC Office of Acquisition Services (two awards, $69 thousand). NHGRI dominates both award volume and dollar concentration, anchoring the customer set with recurring annual purchase orders for software licenses and support. Recent representative awards include a $24 thousand NEI purchase order for software licenses (August 2026), a $15 thousand NHGRI renewal license for sequencing data analysis (August 2025), and a $35 thousand NHGRI software license order (September 2024).

Beyond transactional software licensing, Golden Helix holds two federal research grants from NHGRI under the Small Business Innovation Research program. The company received a Phase II project grant (ultimate completion August 31, 2027) to develop and validate methods for automating identification and interpretation of pharmacogenetic variants from next-generation sequencing data, with integration into electronic health systems using HL7 standards to support clinical decision-making and real-time drug alerts. A related Phase I award (completed March 31, 2024) addressed the same pharmacogenomics workflow capability, demonstrating NHGRI's multi-year commitment to Golden Helix's product development trajectory in clinical genomics.

Award activity shows episodic federal procurement rather than sustained growth or platform relationships. The company recorded three awards in 2024, one in 2025, and one in 2026, following higher volume in 2023 (seven awards) and a baseline in 2022 (three awards). Golden Helix does not maintain parent contract vehicles (GWACs, IDIQs, or BPAs) and transacts exclusively through individual firm fixed-price purchase orders and grants. Three awards carry ultimate completion dates within the next twenty-four months (combined potential value $67 thousand), representing modest recompete exposure. The combined potential value across all seventy-nine awards totals $1.2 million, though obligated dollars across the portfolio reach $7.7 million, reflecting multi-year or multi-license obligations rolled into individual order records.